Merck & Co. Stock News

Calvert Research and Management ranked the 100 most sustainable companies based on over 230 ESG indicators, including workplace diversity and greenhouse-gas emissions. Eight of 78 dividend-paying sustainable companies offer dividends exceeding their share prices, signalling potential buy opportunities for investors. Analysts estimate net gains of 17.47% to 69.69% for the top ten sustainable com...

Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug. The post Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics appeared first on Investor's Business Daily.

Merck's stock is undervalued, trading at less than 4x expected 2024 revenues, despite strong revenue growth from Keytruda and other drugs. Keytruda's revenue is projected to increase by 70% from 2024 to 2032. Declining Gardasil sales in China and competition from Summit Therapeutics and Roche's Tecentriq may have contributed to recent stock volatility.

RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Jefferies London Healthcare Conference.

Dublin, Nov. 14, 2024 (GLOBE NEWSWIRE) -- The "Immunology Biosimilars Market (2024 Edition): Analysis By Indication (Arthritis, Irritable Bowel Disease, Other Indications), By Distribution Channel, By Region, By Country: Market Insights and Forecast (2020-2030)" report has been added to ResearchAndMarkets.com's offering. The Global Immunology Biosimilars market showcased growth at a CAGR of 17....

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and sell an experimental cancer drug, the two companies said on Thursday.

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held clinical-stage biotechnology company, today announced that Merck has entered into an exclusive global license to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. “At Merck, we...

Merck & Co., Inc. (NYSE:MRK ) UBS Global Healthcare Conference November 13, 2024 12:30 PM ET Company Participants Jannie Oosthuizen - President of Human Health of the U.S. Joerg Koglin - SVP of Clinical Research Conference Call Participants Trung Huynh - UBS Trung Huynh Okay, great. I think we're at time here.